Caris Life Sciences And Flatiron Health Join Hands To Expand Access To The Most Comprehensive Molecular Testing Available

With seamless ordering and receipt of Caris molecular profiling findings directly in patient records via the OncoEMR platform, the partnership broadens precision medicine access at the point of treatment.

Fremont, CA: Caris Life Sciences is a premier molecular technology and science firm actively creating and delivering breakthrough solutions to transform healthcare and enhance patient outcomes. Caris has created the large-scale clinico-genomic database and cognitive computing required to analyze and unravel the molecular complexity of disease through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms.

Caris Life Sciences, in collaboration with Flatiron Health, a healthtech company dedicated to assisting cancer centers in thriving and providing better care for patients, collaborated with Caris' market-leading molecular testing portfolio with OncoEMR, a leading cloud-based electronic medical record (EMR) tool. They integrate patient experiences into real-world evidence using clinical and data science to enhance care, guide policy, and advance research. Cancer is astute. They can be smarter together. Flatiron Health is a wholly-owned subsidiary of the Roche Group.

The Molecular Profiling Integration among OncoEMR and Caris provides data-driven clinical decision-making for nearly 2,000 doctors across the Flatiron network, which includes more than 800 distinct cancer care locations around the country. Users may submit Caris orders with fewer clicks and less data entry, follow real-time progress updates and obtain results within OncoEMR thanks to the Molecular Profiling Integration. This improves clinical workflows for clinicians and provides access to Caris molecular findings in the same environment where treatment plans get developed. In addition to providing time-saving benefits throughout the clinician ordering process, the cloud-based connection is enabled—with no associated expense or development work—to any Flatiron network practice that wants it.

Caris's whole array of molecular profile services, including comprehensive whole exome and whole transcriptome sequencing, is now accessible for ordering through the OncoEMR network. Caris is the first and only partner by whole exome and whole transcriptome sequencing expertise to integrate with Flatiron's OncoEMR. It plans to continue working with EMR/EHR systems in academic and community oncology settings on new ways to collaborate genomic results into patient education and care.